Axiom Investors LLC DE Lowers Stock Position in Axon Enterprise, Inc $AXON

Axiom Investors LLC DE lowered its position in Axon Enterprise, Inc (NASDAQ:AXON) by 38.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 84,897 shares of the biotechnology company’s stock after selling 53,633 shares during the period. Axiom Investors LLC DE’s holdings in Axon Enterprise were worth $48,216,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in AXON. Baillie Gifford & Co. raised its holdings in shares of Axon Enterprise by 1,198.7% in the fourth quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock valued at $932,869,000 after purchasing an additional 1,516,099 shares during the last quarter. Norges Bank purchased a new stake in shares of Axon Enterprise in the fourth quarter valued at about $515,764,000. Vanguard Group Inc. raised its holdings in shares of Axon Enterprise by 4.2% in the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock valued at $6,684,217,000 after purchasing an additional 376,904 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Axon Enterprise by 23.0% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 838,289 shares of the biotechnology company’s stock valued at $476,089,000 after purchasing an additional 156,647 shares during the last quarter. Finally, Westfield Capital Management Co. LP raised its holdings in shares of Axon Enterprise by 14.0% in the fourth quarter. Westfield Capital Management Co. LP now owns 831,177 shares of the biotechnology company’s stock valued at $472,051,000 after purchasing an additional 102,025 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on AXON shares. Citigroup reiterated a “buy” rating on shares of Axon Enterprise in a report on Wednesday, February 25th. Craig Hallum reiterated a “buy” rating and issued a $820.00 target price on shares of Axon Enterprise in a report on Wednesday, February 25th. Needham & Company LLC lowered their target price on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a report on Friday, February 20th. Weiss Ratings upgraded shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 8th. Finally, Zacks Research upgraded shares of Axon Enterprise from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $712.75.

Axon Enterprise Price Performance

AXON opened at $452.51 on Wednesday. The company has a market capitalization of $36.47 billion, a price-to-earnings ratio of 181.73, a PEG ratio of 8.56 and a beta of 1.45. The company has a quick ratio of 1.93, a current ratio of 2.27 and a debt-to-equity ratio of 0.49. The firm has a 50-day moving average price of $408.90 and a 200-day moving average price of $490.57. Axon Enterprise, Inc has a twelve month low of $339.01 and a twelve month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.01. The firm had revenue of $807.35 million during the quarter, compared to the consensus estimate of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The company’s revenue was up 33.7% on a year-over-year basis. During the same quarter last year, the company earned $1.47 earnings per share. Equities analysts expect that Axon Enterprise, Inc will post 1.82 EPS for the current year.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon continues to receive favorable analyst coverage, with a “Moderate Buy” consensus and an average price target of $712.75, suggesting Wall Street still sees meaningful upside from current levels.
• Positive Sentiment: The stock has also been supported by strong recent fundamentals, including the company’s latest earnings beat and revenue growth, which helped drive a strong run earlier in the month. Article Title
• Neutral Sentiment: AXON Networks announced the acquisition of Greenwave Systems, a deal that expands its OSS/BSS and wireless orchestration capabilities. This is a strategic growth update, but it appears unrelated to Axon Enterprise’s core public-safety business. Article Title
• Neutral Sentiment: Short-interest data showed no meaningful change in the near term, so it does not appear to be a major driver of the stock’s move.
• Negative Sentiment: Several insiders, including the CEO, president, and CRO, sold shares under pre-arranged trading plans. While these sales may be routine, they can still weigh on investor sentiment when the stock is already trading lower. Article Title
• Negative Sentiment: The stock’s recent pullback also reflects broader profit-taking after a strong monthly run, especially as Axon remains richly valued versus earnings.

Insider Transactions at Axon Enterprise

In other news, insider Elizabeth Reid Coughlin sold 1,554 shares of Axon Enterprise stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $485.00, for a total value of $753,690.00. Following the completion of the transaction, the insider owned 34,024 shares in the company, valued at $16,501,640. This trade represents a 4.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CRO Cameron Brooks sold 1,242 shares of Axon Enterprise stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $500.00, for a total transaction of $621,000.00. Following the completion of the transaction, the executive owned 49,710 shares of the company’s stock, valued at $24,855,000. The trade was a 2.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 39,344 shares of company stock valued at $19,267,315. 4.20% of the stock is currently owned by insiders.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.